Related Experiment Video
Updated: Jun 22, 2026
05:30
Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
Published on: August 8, 2025
Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated
Prasanna Sooriakumaran1, Philippa Gibbs, Geoffrey Coughlin
1Department of Urology, St George's Hospital, London, UK. sooriakumaran@gmail.com
BJU International
|June 5, 2009
Summary
Renal angiomyolipoma (AML) management is complex, particularly in tuberous sclerosis complex (TSC). Selective arterial embolization (SAE) is effective for acute bleeding but limited for long-term AML treatment.
Area of Science:
- Urology
- Nephrology
- Oncology
Background:
- Renal angiomyolipoma (AML) is a rare benign kidney tumor.
- Tuberous Sclerosis Complex (TSC) is associated with larger and multiple AMLs.
- Management strategies for AML vary based on tumor size, symptoms, and TSC status.
Purpose of the Study:
- To evaluate the presentation, management, and outcomes of renal AML.
- To compare different treatment modalities for AML.
- To identify challenges in AML management, especially in TSC patients.
Main Methods:
- Retrospective analysis of 102 patients with renal AML over 10 years.
- Data collection from radiology and clinical genetics databases.
- Assessment of surveillance imaging, interventions (SAE, surgery, RFA), and pharmacological therapy.
Main Results:
- 70 patients had TSC (median tumor size 3.5 cm), 32 were sporadic (median tumor size 1.2 cm).
- Selective arterial embolization (SAE) controlled acute hemorrhage but had limited long-term efficacy and significant complications.
- Surgery and radiofrequency ablation (RFA) showed no complications; sirolimus was used in one patient.
Conclusions:
- AML management is challenging, especially in TSC patients.
- SAE is effective for acute bleeding but not ideal for long-term AML management.
- Novel techniques like focused ablation and mTOR inhibitors warrant further investigation for safer and more effective AML treatment.